Abstract Background The cost of care for inflammatory bowel disease (IBD) has nearly doubled over the last two decades. With an increasing number patients and evolving treatment paradigms utilizing costly but efficacious biologic agents earlier more often, burden is only expected to worsen. Furthermore, IBD carries significant indirect costs lost productivity their caregivers out-of-pocket heal...
